Histologically confirmed PD-L1 status defined NSCLC. Biopsy must be within 70 days of first treatment with pembrolizumab. 
ECOG performance status 2. 
Life expectancy > 12 weeks. 
Uni-dimensionally measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 
Computerised Tomography (CT) scan of chest and abdomen within 28 days of starting pembrolizumab. 
Adequate haematological function: 
Platelet count ≥100 x 109 /L. 
Neutrophils ≥1.5 x 109/L. 
Haemoglobin ≥ 9g/dL. 
Adequate hepatic function: 
Serum bilirubin ≤1.5 x upper limit of normal (ULN). 
Serum transaminases ≤2.5 x ULN. 
Adequate renal function: Creatinine clearance <1.5 times ULN concurrent with creatinine clearance >50 ml/min. 
Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses. 

NCT02733159_inc_T1
Condition
NSCLC
NCT02733159_inc_T2
Qualifier
PD-L1 status
NCT02733159_inc_T3
Procedure
Biopsy
NCT02733159_inc_T4
Temporal
within 70 days of first treatment
NCT02733159_inc_T5
Reference_point
first treatment with pembrolizumab
NCT02733159_inc_T6
Drug
pembrolizumab
NCT02733159_inc_T7
Measurement
ECOG performance status
NCT02733159_inc_T8
Value
2
NCT02733159_inc_T9
Observation
Life expectancy
NCT02733159_inc_T10
Measurement
Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
NCT02733159_inc_T11
Value
Uni-dimensionally measurable
NCT02733159_inc_T12
Condition
disease
NCT02733159_inc_T14
Procedure
Computerised Tomography (CT) scan of chest and abdomen
NCT02733159_inc_T15
Temporal
within 28 days of starting pembrolizumab
NCT02733159_inc_T16
Reference_point
starting pembrolizumab
NCT02733159_inc_T17
Drug
pembrolizumab
NCT02733159_inc_T18
Measurement
Platelet count
NCT02733159_inc_T19
Value
≥100 x 109 /L
NCT02733159_inc_T20
Measurement
Neutrophils
NCT02733159_inc_T21
Value
≥1.5 x 109/L
NCT02733159_inc_T22
Measurement
Haemoglobin
NCT02733159_inc_T23
Value
≥ 9g/dL
NCT02733159_inc_T26
Measurement
Serum bilirubin
NCT02733159_inc_T27
Value
≤1.5 x upper limit of normal (ULN)
NCT02733159_inc_T28
Measurement
Serum transaminases
NCT02733159_inc_T29
Value
≤2.5 x ULN
NCT02733159_inc_T30
Measurement
Creatinine clearance
NCT02733159_inc_T31
Value
<1.5 times ULN
NCT02733159_inc_T32
Temporal
concurrent
NCT02733159_inc_T33
Measurement
creatinine clearance
NCT02733159_inc_T34
Value
>50 ml/min
NCT02733159_inc_T35
Measurement
renal function
NCT02733159_inc_T36
Value
Adequate
NCT02733159_inc_T37
Scope
Creatinine clearance <1.5 times ULN concurrent with creatinine clearance >50 ml/min